Aeroexina Masilinus: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 13: | Line 13: | ||
| '''Type''' || Vaccine | | '''Type''' || Vaccine | ||
|- | |- | ||
| '''Company''' || [[ | | '''Company''' || [[BioLabs]] | ||
|- | |- | ||
| '''Date First Used''' || January 17, 2021 | | '''Date First Used''' || January 17, 2021 | ||
Revision as of 16:40, 17 February 2021
 | This article is incomplete because it is pending further input from participants, or it is a work-in-progress by one author. Please comment on this article's talk page to share your input, comments and questions. Note: To contribute to this article, you may need to seek help from the author(s) of this page. |
| Aeroexina Masilinus | |
| |
| Target Pathogen | Influenza A Virus |
| Type | Vaccine |
| Company | BioLabs |
| Date First Used | January 17, 2021 |
| Type of Vaccine | mRNA |
| Booster Required | No |
| Cost | K/30 |